Asthma Clinical Trial
Official title:
Comparison of Single Dose Versus Two Doses of Oral Dexamethasone in the Management of Acute Asthma Exacerbations in the Pediatric Emergency Department.
Hypothesis: A 2-day course of oral dexamethasone is the superior option for the resolution of symptoms and prevention of relapse in the emergency department (ED) management of mild-moderate asthma exacerbations.
Asthma has become a major public health problem of increasing concern in the US as it is the
most prevalent chronic disease of childhood with over 6 million children under the age of 17
affected 7. Low-income populations, minorities, and children living in inner cities
experience disproportionately higher morbidity and mortality due to asthma. Children who
suffer from asthma often present to the ED or outpatient center for management of their
symptoms and exacerbations. Asthma related ED visits in 2004 were estimated at 1.8 million,
with children younger than 17 accounting for almost half with 754,000 visits 7 Recent
clinical trials have shown the efficacy of dexamethasone in the ED management of asthma. In
Quereshi et al, a randomized study of 533 patients showed that two doses of DEX taken on days
1 and 2 were equally efficacious as 5 days of prednisolone2. However, patients treated with
DEX demonstrated improved compliance with less vomiting, fewer missed days of school and
fewer missed parental workdays. A more recent study by Altamimi et al compared single dose
DEX to 5-day prednisolone1. This double blinded, randomized prospective study of 134 children
concluded that single dose DEX is no worse than 5 days of prednisolone as well.dexamethasone
in the acute management of asthma exacerbation. However, practices vary as to the use of
single dose, two-day dosing and when to administer the second dose. The purpose of this study
is to compare various dosing regimes of dexamethasone in its efficacy in the treatment of
asthma exacerbations. Given the longer duration of action of DEX (36-72 hours), we
hypothesize that 2 doses of DEX given on days 1 & 3 are superior to single dose DEX in
improving symptoms and preventing relapse in the ED management of mild to moderate asthma
exacerbations.
These previous studies show similar efficacy of dexamethasone when compared to the standard
5-day prednisone/prednisolone treatment. . Within the institution, the investigators have
incorporated the use of dexamethasone in the management of acute asthma exacerbations.
However, practices vary as to the use of a single dose, two-day dosing and the timing of the
second dose for those patients receiving two doses of dexamethasone.
The purpose of this study was to determine if single dose oral dexamethasone is as effective
as a 2 dose course of oral dexamethasone in preventing relapse within 7 days for pediatric
asthma patients managed in the ED. Given the long half life of dexamethasone, the
investigators hypothesized that 2 doses given on days 1 and 3 are superior to single dose in
improving symptoms and preventing relapse in the ED management of mild to moderate asthma
exacerbations.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|